logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage [see all figures in this series...]

Part (iii) New injecting drug users (less than 2 years since first injection), 2006 to 2007


Black squares indicate samples with national coverage; blue triangles indicate samples with subnational (including local or regional) coverage.

Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary and some sample sizes are small.

Part of data from Portugal and Hungary include non-IDUs and therefore may underestimate prevalence among IDUs (estimated proportion of non-IDUs in the samples not known).

Data for Spain, Cyprus, Portugal, Romania and Slovenia are limited to prevalence among IDUs in treatment and may not be representative of prevalence among IDUs who are not in treatment. Data for Cyprus and part of data for France are based on self-reported test results, which are less reliable than clinically documented tests.

Data for Poland, Estonia and Lithuania are from 2005. Data for Spain are from 2004. Data for Latvia are from 2003.

Countries are presented by order of increasing prevalence, based on the average of national data or, if not available, of subnational data.

Related links:

Statistical bulletin 2005: Figure INF-5.

For primary sources, study details and data before 2006, see Table INF-10 and Table INF-0.


Reitox national focal points

(see the help page for information about formats etc.)

Page last updated: Monday, 31 August 2009